Study Group: Multiple Sclerosis Neurologists (EU)(?)
Council Members in this Study Group: 102
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Request a survey with this Study Group
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Analysis of:
Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis | pharmalive.com
I am not sure that 4-aminopyridine, a long known drug, will efectively improve walking. As important as the walking ability are other clinical features of MS, e.g. ataxia, dementia or bladder dysfunction. This should also be tested.
Analysis of:
Avicena Highlights Key Collaborators in Amyotrophic Lateral Sclerosis (ALS) Dose Escalation Study | pharmalive.com
There is not much information of the drug ALS-02 in the paper. The term neuroprotection is defined not very well and describes a great number of different molecular mechanisms. The low number of patients will not allow implications for clinical efficacy.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
- Academic Institution*
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Department Chair
- Physician - Director
- Research Scientist
- Director
GLG's 850+ Clients Include:
Fortune 500®
companies
40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
global private equity firms
5 of the top 10
AmLaw firms